Background and importance The recent approval of bevacizumab biosimilar (Beva-Bs) raises the possibility of a more efficient drug therapy. Reference bevacizumab (Beva-Ref) was the cancer drug with the greatest impact in our health area in 2019.
Aim and objectives To evaluate the pharmacoeconomic impact of Beva-Ref in oncological therapy in 2019 and to analyse measures that promote its therapeutic optimisation, such as more efficient dosage regimens (DR) and implementation of Beva-Bs.
Material and methods This was a descriptive retrospective study made in a level II hospital. Farhos-v5.3.3 was used as the pharmacotherapeutic management tool for cancer patients treated with Beva-Ref during 2019. Economic data were collected from the Gestión–Farmatools module.
Pharmacoeconomic analysis was done by therapeutic cost of Beva–Ref use in 2019. Therefore, cost/indication consumption and therapeutic scheme were recorded.
Therapeutic optimisation measures analyses were conducted according to efficient DR, in concordance with the product monograph.
Possibility of using Beva–Bs: hypothetical savings were estimated on 2019’s annual consumption, assuming switching to Beva–Bs: (a) 100% of patients; (b) only new patients.
Variables (Excel): indication, new patient/continuation in 2019, therapeutic scheme and treatment time.
Results 58 patients were treated in 2019. Total cost was 710 842€ and according to indication: nine breast cancer 210 106€ (30%); 25 metastatic colorectal cancer (mCRC) 205 671€ (29%); and 11 ovarian cancer 165 346€ (23%). 41 patients (71%) started treatment with a total cost of 406 897€, mostly: 21 mCRC 169 274€ (42%); 4 breast cancer 74 139€ (18%); and 7 ovarian cancer 65 776€ (16%). Treatment continuations: 17 patients (29%) at a cost of 303 945€, mainly 5 breast cancer 135 967€ (45%), 4 ovarian cancer 99 570€ (33%) and 4 mCRC 36 396€ (12%). The most efficient DR in mCRC was prescribed 100%. In the remaining diagnoses, DR was achieved, except for ovarian/endometrial cancer, with agreement of 45% and 0%, respectively.
With respect to the possibility of using Beva-Bs: a saving of 312 800€ was estimated if switching to Beva-BS in all patients, with savings in breast cancer 92 450€, mCRC 90 500€ and ovarian cancer 72 750€. Considering only new patients, savings would be 179 000€, mostly mCRC, breast and ovarian cancer (74 500€, 32 600€ and 28 900€, respectively).
Conclusion and relevance The 2019 results showed efficient DR, and consequently the potential for cost containment, given the incorporation of Beva-Bs into our therapeutic arsenal, and would be key for universal access to the best therapeutic option.
Conflict of interest No conflict of interest
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.